Organon & Co | OGN - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Bristol-Myers Squibb USD 411M 21M 2026-03
Celltrion KRW 19B 1.96B 2025-06
Cspc Pharmaceutical CNY 6.76M 3.43M 2025-12
Deva Holding AS TRY 272.53M 69.04M 2023-09
Dianthus Therapeutics USD 4.44M 263K 2024-09
Divis Laboratories Ltd INR 60M 0 2026-03
Gilead Sciences USD 240M 15M 2026-03
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Kangmei Pharma CNY 1.82M 150K 2025-09
Knight Therapeutics CAD 3.92M 1.56M 2025-12
Laboratorios Farma EUR 699K 666.2K 2025-06
Medical Developments International AUD 18K 3K 2025-06
Merck USD 479M 67M 2026-03
Neuren Pharmaceuticals AUD 0 0 2024-06
Novartis USD 281M 8M 2025-09
Organigram Holdings CAD 179K 127K 2025-03
Organon & Co USD 111M 17M 2026-03
Ovoca Bio EUR 7K 6K 2022-06
Pharma Mar EUR 117K 1.24M 2025-09
Qiagen NV USD 11.05M 912K 2026-03
Sartorius EUR 49.5M 8.1M 2025-09
Sino Biopharmaceutical CNY 76.87M 114.23M 2024-06
Tilray USD 6.7M 2.73M 2025-06
Zealand Pharma A/S 7.07M 74K 2025-12